Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 7/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 9/20 | 0.34 |
| ▸ | PDE4A | P27815 | 7/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.34 |
| ▸ | F2 | P00734 | 2/20 | 0.31 |
| ▸ | F10 | P00742 | 2/20 | 0.31 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL583869 | 0.97 | NR3C1 (0.40) | POLBNR3C1PDE4BPDE4APDE4C | |
| SCHEMBL1474432 | 0.85 | POLB (0.40) | POLBNR3C1PDE4BPDE4APDE4C | |
| SCHEMBL1471559 | 0.85 | PDE4B (0.39) | POLBNR3C1PDE4BPDE4APDE4C | |
| SCHEMBL1474258 | 0.83 | NR3C1 (0.39) | POLBNR3C1PDE4BPDE4APDE4C | |
| SCHEMBL1472270 | 0.82 | NR3C1 (0.42) | POLBNR3C1PDE4BPDE4APDE4C | |
| SCHEMBL1472267 | 0.82 | NR3C1 (0.43) | POLBNR3C1PDE4BPDE4APDE4C | |
| SCHEMBL1472344 | 0.80 | PDE4B (0.47) | PDE4B | |
| SCHEMBL1472103 | 0.80 | POLB (0.39) | POLBNR3C1PDE4BPDE4APDE4C | |
| SCHEMBL583871 | 0.79 | NR3C1 (0.37) | POLBNR3C1PDE4BPDE4APDE4C | |
| SCHEMBL582945 | 0.79 | NR3C1 (0.37) | POLBNR3C1PDE4BPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110130403-A1 | PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2011-06-02 | — | — | US | claimed |
| US-7915286-B2 | Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2011-03-29 | — | — | US | claimed |
| US-20090306129-A1 | SUBSTITUTED PYRAZOLO [3,4-B] PYRIDINES AS PHOSPHODIESTERASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2009-12-10 | — | — | US | claimed |
| US-20110130403-A1 | PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2011-06-02 | — | — | US | disclosed |
| US-7915286-B2 | Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2011-03-29 | — | — | US | disclosed |
| US-20090306129-A1 | SUBSTITUTED PYRAZOLO [3,4-B] PYRIDINES AS PHOSPHODIESTERASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306129-A1 | SUBSTITUTED PYRAZOLO [3,4-B] PYRIDINES AS PHOSPHODIESTERASE INHIBITORS | PDE3B, PDE4B, PDE3A | POLB 775/4885NR3C1 3658/4885PDE4B 2/4885 |
| US-20110130403-A1 | PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | PDE4A, PDE3B, PDE4B | POLB 1829/4885NR3C1 690/4885PDE4B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.